The selective inhibitor of BCL2, ABT199 (venetoclax), has been approved for the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) [9, 10], highlighting the potential of this targeted treatment therapy. This evidence concerns the gene BCL2 and acute myeloid leukemia.